ZERO Prostate Cancer Response to the American Cancer Society's Updated Prostate Cancer Screening Guidelines

Today's updated guidelines from the American Cancer Society (ACS) are a meaningful step forward in the fight for early detection of prostate cancer. For years, ambiguity around screening created muddled public health messaging, leaving men and their doctors without clear direction. That uncertainty has created barriers to early detection. A direct recommendation for regular PSA-based screening gives those with a prostate and their providers something concrete to act on, and we stand with ACS on this issue.

We are especially encouraged by the recommendation for annual screening beginning at age 45 for Black men and men with a strong family history. Black men experience a 67% higher incidence and nearly double the mortality rate of prostate cancer compared to White men, and for years this disparity has not been reflected in national guidelines. However, the elevated risk facing veterans exposed to harmful chemicals during service, or men carrying a known genetic mutation, even without direct prostate cancer family history, demands the same urgency. At ZERO, we still encourage those at high risk to begin conversations about baseline testing at or around age 40.

Equally important, the updated guidelines recognize that early detection must be paired with appropriate follow-up care. We applaud ACS for recommending additional evaluation, including MRI and/or biomarker testing for most men with a confirmed elevated PSA, to help determine whether a biopsy is necessary. We also strongly support offering active surveillance as an initial management option for men diagnosed with low-risk prostate cancer. The goal is not simply to screen more men. It is to find potentially life-threatening cancers early while avoiding unnecessary procedures and treatment. Every man deserves to understand his individual risk, make informed decisions, and have access to appropriate care.

"These guidelines represent an important shift in how we approach prostate cancer early detection," said Courtney Bugler, President and CEO of ZERO Prostate Cancer. "But recommendations alone won't save lives. We have to make sure men can access screening, understand their results, and get the follow-up care they need. Early detection and avoiding unnecessary treatment are not competing priorities. Both are essential to improving outcomes for men and families impacted by prostate cancer."